-
GuidelinesPublication 2016Decision Models in Clinical Preventive Services Recommendations
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on …
The U.S. Preventive Services Task Force (USPSTF) develops evidence-based recommendations about preventive care based on comprehensive systematic reviews of the best available evidence. Decision models provide a complementary, quantitative approach to support the USPSTF as it deliberates about the evidence and develops recommendations for clinical and policy use. This article describes the rationale for using modeling, an approach to selecting topics for modeling, and how modeling may inform recommendations about clinical preventive services.
Policy/Regulation | Health Outcomes | Evidence Synthesis | Mathematical Models | Decision Analysis | Health Systems | Health/Medicine | North America -
NewsPublication 2017C.D.C. Panel Recommends a New Shingles Vaccine
In a New York Times report, the Centers for Disease Control and Prevention recommended the …
In a New York Times report, the Centers for Disease Control and Prevention recommended the use of a new vaccine to prevent herpes zoster (“shingles”) among adults in the US. “In an unusually close vote, an advisory panel to the Centers for Disease Control and Prevention on Wednesday recommended the use of a new vaccine to prevent shingles over an older one that was considered less effective. "The decision was made just days after the…
Policy/Regulation | Infectious Diseases | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | North America -
NewsPublication 2017FDA Advisers Recommend Approval of New Shingles Vaccine
An FDA advisory panel voted 11-0 on Wednesday in favor of approving the Shingrix herpes …
An FDA advisory panel voted 11-0 on Wednesday in favor of approving the Shingrix herpes zoster vaccine for adults aged 50 and older, Reuters reports. In clinical trials, the new vaccine conferred greater protection against herpes zoster among older adults, relative to the currently marketed zoster vaccine, Zostavax. In particular, 4 years after immunization, Shingrix was about 90% effective in adults older than 70, while the efficacy of Zostavax waned with time, according to Reuters.…
Policy/Regulation | Infectious Diseases | Economics/Finance | Government/Law | Health/Medicine | North America
3 Shown
General Resources
Teaching Resources
Collections
Format
Learner Level
Teaching Topic